About
The Yuhan Corporation is a South Korean conglomerate that was founded on September 1, 1926, under the name "Chosun Pharmaceutical Company". The company is headquartered in Seoul and employs more than 5,000 people worldwide. History: The Yuhan Corporation started as a small company with a single product, a fish oil-based ointment called "Yuksundo". The company worked hard to improve its products and expand its market, eventually expanding into other business areas such as the production of antibiotics and diabetes treatments. In the early 1950s, the company also ventured into the research and development of other pharmaceuticals. In 1962, Yuhan became a publicly traded company and received a variety of awards in the following years, including several Korean Industrial Awards. Since its inception, the company has remained committed to improving people's lives through innovation and science. Business model: The Yuhan Corporation is a pharmaceutical company that focuses on the development, manufacturing, and marketing of drugs and other health products. The company also makes investments in innovative technologies and healthcare startups. Over the years, Yuhan has expanded its business through partnerships with other companies and acquisitions of companies such as LGL Holdings and SillaJen Inc. The company also engages in international business relations, such as selling its products and medications in other countries. Divisions: The Yuhan Corporation has four main business divisions: Medical Research and Development, Drug Manufacturing, Biotechnology Product Development, and Health Product Production. The first division is coordinated by Yuhan Research & Development Co. Ltd, while drug manufacturing is done by Yuhan Manufacturing Co. Ltd. Biotechnology is done by Yuhan Biomedical Research Institute, and the health product segment is handled by Yuhan Healthcare. Products: Yuhan's products are diverse and include a wide range of drugs and health products. The company is involved in the production of antibiotics, analgesics, vein treatment agents, diabetes medications, cardiovascular drugs, and other pharmaceutical products. Other products also include cosmetics, oral care products, and dermatology drugs. Some of Yuhan's well-known products include the antibiotic Ceclor, a medication for the treatment of diabetes and metabolic disorders, as well as apple-based cosmetic products. All Yuhan products are manufactured according to strict quality standards and are known for their effectiveness and safety. Conclusion: The Yuhan Corporation has evolved into a diverse and innovative company focused on the production of drugs and health products. The company has a long history with many successes and has established itself as one of the major forces in the South Korean economy over the past decades. Yuhan's mission to create better healthcare remains as relevant today as it was at the time of its founding.
Annual results
Reported figures, KRW · revenue up 5.7% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 2.2T | 194B | 8.9% | — |
| 2024 | 2.1T | 70.7B | 3.4% | — |
| 2023 | 1.9T | 136B | 7.3% | — |
| 2022 | 1.8T | 95.1B | 5.4% | — |
| 2021 | 1.7T | 103B | 6.1% | — |
Dividends per share
000100.KS in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Yuhan Corp are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.